ESR1 and carcinoma: Nevertheless, low ER expression (1% to 10% of weakly positive cells) must be reported, as recommended by the current guidelines [1], as these tumors are heterogenous, some of them with similar characteristics to ER-negative carcinomas [29,30], and do not benefit as much from endocrine treatments.